Tilray Brands, Inc. finds itself in a critical position as it navigates a potential delisting from the Nasdaq exchange. The company received a formal notification of non-compliance on March 25, 2025, after its share price fell below the mandatory $1.00 minimum bid requirement. A definitive deadline now looms on September 21, 2025, by which time the company must rectify this situation to maintain its listing.
The Path to Compliance
To satisfy Nasdaq’s requirements, Tilray’s stock must achieve a closing price of at least one dollar for ten consecutive trading sessions. Failure to meet this condition will trigger the delisting process. While this appears straightforward, executing such a sustained price recovery presents a significant challenge for the beleaguered cannabis producer.
In preparation for this scenario, the company’s leadership secured shareholder approval in June 2025 for a potential reverse stock split. The authorized ratio ranges from 1-for-10 to 1-for-20. This maneuver would mechanically increase the share price by consolidating outstanding shares, thereby addressing the immediate Nasdaq deficiency. Management, however, has yet to execute this strategy, indicating a careful approach to timing this measure for maximum effect.
Underlying Financial Performance
The company’s fiscal year 2025 results, which concluded at the end of May, present a complex picture. Despite generating net revenue of $821 million, Tilray reported a staggering net loss of $2.2 billion. This devastating loss was primarily driven by substantial impairment charges that severely impacted the bottom line.
Should investors sell immediately? Or is it worth buying Tilray?
Amid these challenges, several positive financial indicators emerged:
* A reduction in debt of approximately $100 million
* An expansion in cannabis gross margin from 33% to 40%
* The maintenance of a solid cash position with $256 million in available liquidity
European Operations Provide a Glimmer of Hope
The international segment, particularly in Europe, has emerged as a notable bright spot. Excluding Australia, the company’s cannabis revenue in international markets surged by an impressive 112%. This growth is largely attributed to expanding operations in Germany and other key European markets, positioning the region as a potential engine for future recovery.
The critical question remains whether these positive international trends and available financial strategies can orchestrate a broader turnaround for Tilray. The coming weeks leading up to the September deadline will prove decisive in determining the company’s ability to maintain its Nasdaq listing and chart a path toward sustainable recovery.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from February 5 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 5.
Tilray: Buy or sell? Read more here...
